Inlivetox
Structure de mise en forme 2 colonnes

URMC


Brief Description

The University of Rochester, founded in 1850, is one of the nation's leading private universities. With just over 4,500 undergraduates, Rochester is one of the smallest and most collegiate in character among the top research universities. The University of Rochester Medical Center forms the centerpiece of the University's health research, teaching, patient care, and community outreach missions. With more than $145 million in federal research funding, UR School of Medicine research funding ranks in the top one-quarter of U.S. medical centers, while the School of Nursing ranks 12th highest in funding. n       Department involved The Environmental Medicine department will be involved in InLiveTox project. The mission of this department is to increase scientific understanding of the health risks posed by contaminants at home, in the workplace, and in the ambient environment.      

Activities in the project

 

URMC is a world-class institution that are widely recognised as experts in assessing the hazard of nanoparticles, especially using animal models. URMC will therefore play a major role in the detailed design of the in vivo experimental protocols, and the subsequent data interpretation. Furthermore, they will conduct parallel experiments to assess the potential for the liver to excrete the InLiveTox nanoparticle panel into bile and therefore eliminate them from the body. URMC will also assess the durability of the nanoparticles in biologically relevant media in order to relate their biopersistence to their potential toxicity in both the in vivo and the in vitro models. Finally, URMC will participate in the design of the InLiveTox in vitro system and the subsequent data analysis, with special emphasis on ensuring that the exposure doses and protocols are relevant to the in vivo exposure scenario.        

Expertise in these activities / Previous experiences

 

Prof. Oberdörster has 40 years’ background in particles and nanoparticles toxicology and pharmacology as detailed below in his CV.       

Key people involved

Prof. Günter Oberdörster is Director, UR-EPA Particulate Matter Center since 1999. After a PhD in pharmacology at the University of Giessen in West Germany in 1961-1964, he worked in Federal Republic of Germany form 1965 to 1979 successively in the Laboratory of Pharmacology, Troponwerk in Cologne, as Assistant Professor in the Inst. for Physiology of the University of Cologne, and in the Fraunhofer Society, Inst. for Toxicology & Aerosol Research. In 1979, he became Visiting Assoc. Prof at the University of Rochester in the Dept. of Radiation Biology and Biophysics. He became Assoc. Prof in 1981 and Prof in 1989. In 1992 he became Prof of toxicology at the University of Rochester in the Dept. of Environ. Med. From 1995 to 1999, he was Head of the Div. of Respiratory Biology & Toxicology, at the Univ. of Roch. School of Medicine. Prof. Oberdörster is/was member of several Advisory Committees and has several Editorial Assignments. n      

Some relevant publications / Patent

 

 

  • Oberdörster, G et al Environmental Health Perspectives 113: 823-839, (2005)
  • Oberdörster, G., et al Reuters’ ScienceWatch, (2008)
  • Jiang, J., et al J. Nanopart. Res. (2008)      

 

 

Links